Results 261 to 270 of about 8,099,813 (387)

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

A lyophilizable LNP vaccine enables STING-reinforced postoperational adjuvant immunotherapy. [PDF]

J Nanobiotechnology
Yang Y, Guo J, Qi J, Deng W, Hu J, Hasan MW, Deng F, Zhou Y, Song Z, Deng W, Chen W.   +10 more
europepmc   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

The Early Recognition of Tumors of the Bladder [PDF]

, 1913
ARTHUR L. CHUTE
openalex   +1 more source

Macrophage Diversity Enhances Tumor Progression and Metastasis

Cell, 2010
Binzhi Qian, J. Pollard
semanticscholar   +1 more source

Research on individualized drug sensitivity detection technology based on bio-3D printing technology for precision treatment of gastrointestinal stromal tumors. [PDF]

Open Life Sci
Tu YY, Huang ZT, Zhang ZY, Liu DL, Qian HL.   +4 more
europepmc   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Ten Cases of Removal of Uterine Tumors by Laparotomy [PDF]

, 1885
John Homans
openalex   +1 more source

Matrix Metalloproteinases: Regulators of the Tumor Microenvironment

Cell, 2010
K. Kessenbrock, V. Plaks, Z. Werb
semanticscholar   +1 more source

Stabilized iRGD modification enhances NY-ESO-1 TCR-T infiltration in solid tumors and synergizes with PD-1 blockade. [PDF]

Cancer Immunol Immunother
Wu Y, Qin L, Wang J, Xie Z, Su X, Li X, Yang Y, Huang R, Zhao M, Zhao L, Zou Z.   +10 more
europepmc   +1 more source